Last €2.18 EUR
Change Today +0.068 / 3.22%
Volume 8.2K
B8F On Other Exchanges
As of 11:36 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

biofrontera ag (B8F) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/19/14 - €4.15
52 Week Low
09/17/14 - €2.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOFRONTERA AG (B8F)

Related News

No related news articles were found.

biofrontera ag (B8F) Related Businessweek News

No Related Businessweek News Found

biofrontera ag (B8F) Details

Biofrontera AG, a biopharmaceutical company, is engaged in the discovery, development, and distribution of dermatological drugs and dermatological-tested cosmetics for the treatment and care of diseased skin. Its products include Ameluz, a prescription drug for the treatment of actinic keratosis, a superficial skin cancer; BF-RhodoLED, a lamp for photodynamic therapy; and Belixos, a cream with herbal ingredients for the care of inflamed, itchy, and flaky skin, such as localized itching, insect bites, burns, nuerodermatitis, and psoriasis. The company is also developing BF-derm1, which is in Phase II clinical trial for the treatment of chronic and antihistamine-refractory urticaria; and BF-1, a specific serotonin receptor antagonist that is in Phase I clinical trial for migraine prophylaxis. In addition, it focuses on developing Ameluz for other superficial cancer and warts. The company was founded in 1997 and is headquartered in Leverkusen, Germany.

39 Employees
Last Reported Date: 08/29/14
Founded in 1997

biofrontera ag (B8F) Top Compensated Officers

Co-Founder, Chairman of Management Board and ...
Total Annual Compensation: €412.0K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €100.0K
Compensation as of Fiscal Year 2013.

biofrontera ag (B8F) Key Developments

Biofrontera AG Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2014

Biofrontera AG reported unaudited consolidated earnings results for the six months ended June 30, 2014. For the six months, the company reported sales revenue of EUR 1,216,529.60 compared to EUR 1,385,150.17 reported a yea ago. Loss from operations was EUR 4,942,740.77 compared to EUR 3,348,008.98 reported a yea ago. Loss before income tax was EUR 5,412,589.78 compared to EUR 3,697,809.74 reported a yea ago. Loss for the period was EUR 5,418,713.78 or EUR 0.25 per diluted share compared to EUR 3,697,809.74 or EUR 0.22 per diluted share reported a yea ago. Net cash used in operations was EUR 4,395,214.47 compared to net cash flow from operations of EUR 4,397,064.78 reported a yea ago. Purchase of intangible and tangible assets was EUR 85,524.50 compared to EUR 125,556.99 reported a yea ago.

Biofrontera AG to Report First Half, 2014 Results on Aug 29, 2014

Biofrontera AG announced that they will report first half, 2014 results on Aug 29, 2014

Biofrontera AG, H1 2014 Earnings Call, Aug 29, 2014

Biofrontera AG, H1 2014 Earnings Call, Aug 29, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
B8F:GR €2.18 EUR +0.068

B8F Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for B8F.
View Industry Companies

Industry Analysis


Industry Average

Valuation B8F Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.6x
Price/Book 8.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOFRONTERA AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at